The first sign of a good pharmaceutical intervention for COVID-19! A properly conducted randomized control trial (RCT) using Remdesivir has shown that its use accelerates recovery from infection. While it is too soon to see if it also helps lower mortality, the data is certainly trending that way.
The trial was stopped early, because the evidence was so clear that it was beneficial for patients and they wanted to get the patients, who were receiving the saline placebo, onto the treatment. This is the type of breakthrough that was needed to keep more people out of the ICU and get them out of hospital sooner.
A second study, using a therapeutic monoclonal antibody is also showing real promise as well and I hope the data from that trial is released soon. These two treatments when used together could be a game changer for the course of infection!
Erin S. Bromage, Ph.D., is an Associate Professor of Biology at the University of Massachusetts Dartmouth. Dr. Bromage graduated from the School of Veterinary and Biomedical Sciences James Cook University, Australia where his research focused on the epidemiology of, and immunity to, infectious disease in animals. His Post-Doctoral training was at the College of William and Mary, Virginia Institute of Marine Science in the Comparative Immunology Laboratory of late Dr. Stephen Kaattari.
Dr. Bromage’s research focuses on the evolution of the immune system, the immunological mechanisms responsible for protection from infectious disease, and the design and use of vaccines to control infectious disease in animals. He also focuses on designing diagnostic tools to detect biological and chemical threats in the environment in real-time.
Dr. Bromage joined the Faculty of the University of Massachusetts Dartmouth in 2007 where he teaches courses in Immunology and Infectious disease, including a course this semester on the Ecology of Infectious Disease which focused on the emerging SARS-CoV2 outbreak in China.
Dr. Bromage I understand what you think in this article now a day every country face very critical situation and I always pry for get rid of COVID 19. http://guidelovers.com/best-cd-player-for-kids/
Dr. Bromage, I am curious what you think of this article from statnews in which they describe the potential benefits of focusing on GS-441524 instead of Remdesivir. I realize that without any steps taken towards FDA approval, there may be more roadblocks, but if it is a more effective, easier to produce treatment, then it certainly seems worthy of investigation.
https://www.statnews.com/2020/05/14/gilead-should-ditch-remdesivir-and-focus-on-its-simpler-safer-ancestor/
I think it is worth noting that in hospitals, the use of high-dose vitamin C, intravenously, has been very effective at treating the very worst aspects of this disease. First noted in Shanghai, the official recommendation from the doctors and the administration became to include high dose vitamin C. Mortality rates plunged, as did length of hospital stays.They also began to use very high doses of ascorbic acid, orally, for all new admittees to the hospital, as well as for staff. Reported here by Dr. Richard Cheng, an American board certified physician, who has been on the front lines in China:
http://orthomolecular.org/resources/omns/v16n18.shtml#Ref1
Very sobering and thoughtful, information. Thanks
Thank you from an Aussie in Perth who is very appreciative of your outstanding informative reports based on science its such a change.